AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

Not only did AbbVie’s Skyrizi claim first place in the full-year ranking with nearly $377 million spent on 20 separate ads for the drug, according to iSpot.TV’s analysis, but, with two other ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Louis Navellier is a prominent American investor, author, and financial analyst ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been underperforming ...

New prices aim to save billions by 2027. Vandana Singh Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal Johnson & Johnson's ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

US FDA approves expanded use of Lilly's bowel disease drug Healthcare & Pharmaceuticalscategory· January 16, 2025 AbbVie plans to "commit less capital" towards experimental medicines for ...